161 related articles for article (PubMed ID: 18559790)
1. Sorafenib-induced eruptive melanocytic lesions.
Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
[No Abstract] [Full Text] [Related]
2. Non-pigmenting fixed drug eruption induced by sorafenib.
Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K
Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556
[No Abstract] [Full Text] [Related]
3. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
4. Invasive squamous cell carcinoma and sorafenib in a black patient.
Donaldson MR; Stetson CL; Smith JL
Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
[No Abstract] [Full Text] [Related]
5. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Hong DS; Reddy SB; Prieto VG; Wright JJ; Tannir NM; Cohen PR; Diwan AH; Evans HL; Kurzrock R
Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
[TBL] [Abstract][Full Text] [Related]
6. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Ravaud A; Digue L; Trufflandier N; Smith D
Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
[No Abstract] [Full Text] [Related]
7. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
8. [Squamous cell carcinoma in a patient receiving sorafenib].
Adnot-Desanlis L; Bernard P; Reguiaï Z
Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
[No Abstract] [Full Text] [Related]
10. Delayed onset perforating folliculitis associated with sorafenib.
Batalla A; Menéndez L; Blay P; Curto JR
Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
[No Abstract] [Full Text] [Related]
11. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Bhojani N; Jeldres C; Patard JJ; Perrotte P; Suardi N; Hutterer G; Patenaude F; Oudard S; Karakiewicz PI
Eur Urol; 2008 May; 53(5):917-30. PubMed ID: 18054825
[TBL] [Abstract][Full Text] [Related]
12. Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Galán Brotons A; Borrás-Blasco J; Rosique-Robles JD; Vicent Verge JM; Casterá ME
Clin Transl Oncol; 2008 Dec; 10(12):844-6. PubMed ID: 19068457
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
Paz C; Querfeld C; Shea CR
J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
[No Abstract] [Full Text] [Related]
14. Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
Dranitsaris G; Vincent MD; Yu J; Huang L; Fang F; Lacouture ME
Ann Oncol; 2012 Aug; 23(8):2103-2108. PubMed ID: 22228446
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
16. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
17. [Eruptive nevi associated with sorafenib treatment].
Bennani-Lahlou M; Mateus C; Escudier B; Massard C; Soria JC; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Oct; 135(10):672-4. PubMed ID: 18929917
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Dubauskas Z; Kunishige J; Prieto VG; Jonasch E; Hwu P; Tannir NM
Clin Genitourin Cancer; 2009 Jan; 7(1):20-3. PubMed ID: 19213663
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induced eruptive melanocytic lesions.
Uhlenhake EE; Watson AC; Aronson P
Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
[TBL] [Abstract][Full Text] [Related]
20. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
